26.59
+0.81(+3.14%)
Currency In NaN
| Previous Close | 25.78 |
| Open | 26.22 |
| Day High | 27.03 |
| Day Low | 26.16 |
| 52-Week High | 42.27 |
| 52-Week Low | 6.43 |
| Volume | 19,181 |
| Average Volume | 738,034 |
| Market Cap | 970.47M |
| PE | 22.16 |
| EPS | 1.2 |
| Moving Average 50 Days | 21.59 |
| Moving Average 200 Days | 14.65 |
| Change | 0.81 |
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
GlobeNewswire Inc.
Sep 11, 2025 8:05 PM GMT
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines
Rapport Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Sep 10, 2025 1:17 AM GMT
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines
Rapport Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Sep 08, 2025 8:05 PM GMT
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines